⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345383 | 0.83 | — | — | |
| SCHEMBL2010713 | 0.78 | CES2 (0.37) | — | |
| SCHEMBL2490961 | 0.77 | — | — | |
| Urea SCHEMBL3111133 | 0.76 | — | — | |
| SCHEMBL24297077 | 0.75 | — | — | |
| SCHEMBL6668639 | 0.75 | CES2 (0.36) | — | |
| SCHEMBL22325195 | 0.75 | CES2 (0.36) | — | |
| SCHEMBL6712841 | 0.75 | CES2 (0.36) | — | |
| SCHEMBL30661132 | 0.75 | CES2 (0.36) | — | |
| SCHEMBL10403326 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566716-B2 | Imidazopyrazines as Raf inhibitor compounds | ARRAY BIOPHARMA INC. (US) | 2009-07-28 | — | — | US | claimed |
| EP-1902056-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| US-20060281751-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA, INC. | 2006-12-14 | — | — | US | claimed |
| WO-2006125101-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-11-23 | — | — | WO | claimed |
| US-9090640-B2 | Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof | WAKE FOREST UNIVERSITY | 2015-07-28 | — | — | US | disclosed |
| US-8470795-B2 | Antisense modulation of kinesin-like 1 expression | ISIS PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20130059777-A1 | MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOCASE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20100240738-A1 | ANTISENSE MODULATION OF KINESIN-LIKE 1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7566716-B2 | Imidazopyrazines as Raf inhibitor compounds | ARRAY BIOPHARMA INC. (US) | 2009-07-28 | — | — | US | disclosed |
| EP-1902056-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20060281751-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA, INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2006125101-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| EP-1082456-A4 | ANTISENSE MODULATION OF CD40 EXPRESSION | ISIS PHARMACEUTICALS INC (US) | 2002-07-31 | — | — | EP | disclosed |
| EP-1082456-A1 | ANTISENSE MODULATION OF CD40 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999057320-A1 | ANTISENSE MODULATION OF CD40 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1999-11-11 | — | — | WO | disclosed |
| US-4914206-A | ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-04-03 | — | — | US | disclosed |
| EP-0226896-A2 | Lankacidin derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-07-01 | — | — | EP | disclosed |